Sun Pharma jumps 5% on series of clarifications

The drug major said that its domestic formulations distribution shall be transitioned from Aditya Medisales, the current distributor, to a wholly-owned subsidiary of Sun Pharma.

Sun Pharma
SI Reporter New Delhi
Last Updated : Jan 22 2019 | 10:29 AM IST
Shares of Sun Pharma jumped as much as 5.1 per cent to Rs 418.70 in the early trade on BSE after the company made a series of clarifications and changes in its filing to the bourses. 

The drug major said that its domestic formulations distribution shall be transitioned from Aditya Medisales, the current distributor, to a wholly-owned subsidiary of Sun Pharma and the change will be made effective by Q1FY20, post receipt of all requisite regulatory approvals. CLICK HERE TO READ THE PRESS PRELEASE

This apart, the firm also announced unwinding of a transaction with Atlas Global Trading (Atlas). "This assignment will ensure that the Loans & Advances given to Atlas will be settled. On conclusion of this transaction, in the consolidated balance sheet, this loan and the obligation will cease to exist as it gets squared up. This transaction is expected to be concluded in FY19," it said in its press release. 

Further, Sun Pharma also confirmed that neither any loans nor guarantees have been given to Suraksha Realty. "Sun Pharma would like to dispel all falsehoods being spread about its financial dealings with Suraksha Realty. The company states unequivocally that it does not have any financial transactions with Suraksha Realty," it said. 

Lastly, it added that the company has initiated steps to induct SRBC & CO LLP, its statutory auditors, as auditors of their subsidiaries that are currently audited by Valia & Timbadia. 

Last Friday, shares of the pharma company crashed to a six-year low after a news report suggested new whistleblower documents had been sent to regulator Securities and Exchange Board of India (Sebi). The report stated that huge transactions allegedly took place between Aditya Medisales and private companies of Sun Pharma's promoters between 2014 and 2017.

The company, however, later in the day clarified it was not privy to the news reports.

At 10:11 am, the stock was trading 4.86 per cent higher at Rs 418 apiece on BSE. In comparison, the S&P BSE Sensex was trading 177 points or half a per cent lower at 36,402. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story